Expanding **TREATMENT OPTIONS**
for **CANCER PATIENTS**

**ANNUAL IMPACT SHEET 2014**

**MISSION & VISION**

**MAIN ACTIVITIES**
- Research projects
- Patient support

**TEAM**

**FINANCIAL PERFORMANCE**
Our vision
• As a society, we need to ensure that no treatment option is left untapped.

Our dual mission
• Funding promising breakthrough therapies which are commercially neglected
• Free comprehensible cancer information

1. Research Projects

PRECLINICAL PROJECTS (total 11.9%)
- Cryoablation and non-toxic products (7.45%)
- Gloriosa superba extract (1.77%)
- Radiotherapy & Immune Response (2.68%)

CLINICAL PROJECTS (total 52.07%)
- Nitroglycerine patch & radiotherapy (< 1%)
- Metzolimos (3.20%)
- B-AHEAD 3 (5.37%)
- Artesunate (1.11%)
- Fluvabrex (< 1%)
- Ketorolac (13.87%)
- Ultra low dose chemotherapy (2.04%)
- Vagus Nerve stimulation (6.38%)
- Boost your mind (8.62%)
- Adoptive T-cell therapy (10.71%)
- EFFECT - Effectiveness of Endometrial Cancer Treatments in collaboration with the Belgian Cancer Registry (1.74%)
- Verelst Uterine Fund in collaboration with KU Leuven, Belgium (34.29%)

2. Patient Support

In 2010-2014 434 patients received information via info@anticancerfund.org.

<table>
<thead>
<tr>
<th>Guides for patients with general information</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>10</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Guides for patients with information per cancer type (ESMO)</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>16</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Information sheets for patients on therapies (mainstream &amp; non-mainstream)</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>267</td>
</tr>
</tbody>
</table>

ACF-supported research projects are currently scheduled to include over 544 patients up to end 2014.

- Endometrial cancer: 10 patients
- Colorectal cancer: 10 patients
- Lung cancer: 60 patients
- Liver cancer: 15 patients
- Breast cancer: 320 patients
- Osteosarcoma: 26 patients
- Melanoma: 12 patients
- All cancer types: 56 patients
- Optic-pathway glioma: 35 patients

For a detailed list of our projects, contact us or consult our website:
NEW PROJECTS

New project - ReDO - Repurposing Drugs in Oncology

The Repurposing Drugs in Oncology (ReDO) project is a collaboration with the US not-for-profit organisation Global Cures. The aim of the project is straightforward – to identify a range of existing non-cancer drugs which show strong evidence of anti-cancer activity and which have the potential for clinical use. There is a broad spectrum of drugs that the project has identified, many of them available as cheap generics, including antibiotics, antifungals and antiparasitics. Taking evidence from a variety of sources, the ReDO project has reviewed, summarised and published the results in peer-reviewed journals.

EVENT - Roundtable conference - TIL in ovarian cancer

In June 2014 a round table conference was organized in Brussels by the Anticancer Fund aiming to cooperate and share expertise to efficiently extend the successful results of adoptive TIL transfer-therapy in melanoma to ovarian cancer. Adoptive TIL therapy has a profound better complete response rate compared to all other treatments for advanced melanoma and results in durable responses. Two projects were initiated as a result of this meeting: ‘Immunotherapy by adoptive T cell infusion in the event of advanced ovarian cancer’ (University Hospital Herlev, Denmark) and ‘Combined Chemo- and Adoptive T cell-therapy (ACT) as treatment for recurrent epithelial ovarian carcinoma’ (Leiden University Medical Centre, the Netherlands). The meeting and the project were supported by OvaCure (a Danish non-profit organization focused on the fight against ovarian cancer).

OUR TEAM with a focus on scientists and medical doctors

We welcomed 4 new team members in 2014.

<table>
<thead>
<tr>
<th>Country</th>
<th>Project area</th>
<th>Budget</th>
</tr>
</thead>
<tbody>
<tr>
<td>UK</td>
<td>ADVANCED BREAST CANCER</td>
<td>€ 263,000</td>
</tr>
<tr>
<td></td>
<td>- randomised phase II trial</td>
<td></td>
</tr>
<tr>
<td>France</td>
<td>OSTEOSARCOMA (BONE TUMOR)</td>
<td>€ 165,000</td>
</tr>
<tr>
<td></td>
<td>- phase I trial</td>
<td></td>
</tr>
<tr>
<td>The Netherlands</td>
<td>NON-SMALL CELL LUNG CANCER</td>
<td>€ 78,000</td>
</tr>
<tr>
<td></td>
<td>- phase II trial</td>
<td></td>
</tr>
<tr>
<td>Belgium</td>
<td>HEPATOCELLULAR CARCINOMA (LIVER CANCER)</td>
<td>€ 62,000</td>
</tr>
<tr>
<td></td>
<td>- phase I trial</td>
<td></td>
</tr>
</tbody>
</table>

An Van Nuffel, Ph.D.
Program manager immunotherapy

Fabienne Van de Keere, Ph.D.
Expert cellular immunotherapy

Sarah Vandenbroek
Team Assistant

Pan Pantziarka, Ph.D.
Expert Drug Repurposing
FINANCIAL PERFORMANCE

Expenses in 2014

<table>
<thead>
<tr>
<th>Category</th>
<th>% of Total</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>INFORMATION</td>
<td>24.4%</td>
<td>€ 402,294</td>
</tr>
<tr>
<td>COMMUNICATION &amp; FUNDRAISING</td>
<td>13.1%</td>
<td>€ 217,173</td>
</tr>
<tr>
<td>ADMINISTRATION</td>
<td>7.4%</td>
<td>€ 122,413</td>
</tr>
<tr>
<td>RESEARCH PROJECTS</td>
<td>55.1%</td>
<td>€ 910,771</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td></td>
<td>€ 1,652,651</td>
</tr>
</tbody>
</table>

**TOTAL EXPENDITURE** for 2014 was € 1,652,651.
This expenditure is divided mainly between information & communication activities and the amount spent on supporting our research projects.

Amount spent on

- **INFORMATION**: € 402,294
  - This expenditure covers two main areas:
  1. website costs, including updating information and adding new information (€ 308,211)
  2. the costs of maintaining our patient support via info@anticancerfund.org (€ 94,083)

- **COMMUNICATION AND FUNDRAISING**: € 217,173
  - This includes a dedicated full-time fundraising employee.

- **ADMINISTRATION**: € 122,413
  - This covers the general administrative support at the Anticancer Fund.

- **RESEARCH PROJECTS**: € 910,771
  - This covers all costs, including the personnel cost of the ACF employees managing specific projects, of the preclinical projects, the clinical projects, the Verelst Uterine Fund and the EFFECT project.

**Total amount spent**: € 1,650,000 well spent in the fight against cancer!